Nektar Therapeutics (NKTR) Other Non-Current Assets (2010 - 2026)
Nektar Therapeutics (NKTR) posted quarterly Other Non-Current Assets of $11.2 million for Q1 2026, up 108.44% year-over-year from $5.4 million in Q1 2025, and down 20.53% quarter-over-quarter from $14.1 million in Q4 2025.
Nektar Therapeutics (NKTR) Other Non-Current Assets (2010 - 2026) Analysis & Trends
Nektar Therapeutics' Other Non-Current Assets history runs 17 years deep, the most recent figure standing at $11.2 million for Q1 2026.
- In Q1 2026, Other Non-Current Assets rose 108.44% year-over-year to $11.2 million; the TTM figure through Mar 2026 stood at $11.2 million (up 108.44% YoY), while the FY2025 annual figure was $14.1 million, up 204.28% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $11.2 million, down from $14.1 million in the prior quarter.
- The five-year high for Other Non-Current Assets was $33.1 million in Q3 2024, with the low at $1.4 million in Q1 2023.
- The 5-year median for Other Non-Current Assets is $4.6 million (2023), against an average of $6.4 million.
- The sharpest annual moves came in 2024 and 2025: Other Non-Current Assets soared 630.78% in 2024, then slumped 84.4% in 2025.
- Nektar Therapeutics' Other Non-Current Assets stood at $2.2 million in 2022, then jumped by 106.86% to $4.6 million in 2023, then rose by 0.06% to $4.6 million in 2024, then surged by 204.28% to $14.1 million in 2025, then retreated by 20.53% to $11.2 million in 2026.
- Business Quant data shows NKTR's Other Non-Current Assets at $11.2 million in Q1 2026, $14.1 million in Q4 2025, and $5.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Nektar Therapeutics | 1.49 Bn | 919.46 Mn | 3.16 Mn | 11.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11.24 Mn |
| Dec 31, 2025 | 14.14 Mn |
| Sep 30, 2025 | 5.16 Mn |
| Jun 30, 2025 | 5.02 Mn |
| Mar 31, 2025 | 5.39 Mn |
| Dec 31, 2024 | 4.65 Mn |
| Sep 30, 2024 | 33.05 Mn |
| Jun 30, 2024 | 4.31 Mn |
| Mar 31, 2024 | 4.66 Mn |
| Dec 31, 2023 | 4.64 Mn |
| Sep 30, 2023 | 4.52 Mn |
| Jun 30, 2023 | 1.65 Mn |
| Mar 31, 2023 | 1.41 Mn |
| Dec 31, 2022 | 2.25 Mn |
| Sep 30, 2022 | 2.32 Mn |
| Jun 30, 2022 | 2.23 Mn |
| Mar 31, 2022 | 1.52 Mn |
| Dec 31, 2021 | 2.74 Mn |
| Sep 30, 2021 | 1.84 Mn |
| Jun 30, 2021 | 344,000.00 |